Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

Both belong to a newer class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. Nurtec Orally Disintegrating Tablet (ODT) is a prescription medication taken to treat and ...